Immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors.
Immatics was chosen from more than 2,100 technology start-ups, judged by a panel of industry experts ranging from venture capital to entrepreneurs. The awards were showcased on 18-19 May 2012 at 2012 TiEcon, the world’s largest convention dedicated to entrepreneurs, in Santa Clara, California.
Paul Higham, immatics’ CEO, said: “The TiE50 Award acknowledges immatics’ significant progress in developing innovative therapies for difficult to treat cancers. The positive phase 2 results that we have reported with IMA901 for renal cell carcinoma and IMA910 for colorectal cancer highlight the potential for our multi-peptide cancer vaccines to play an important role in improving the treatment of cancer. The judges were impressed with the rapid development of our vaccines, particularly the fast transition of IMA901 into the phase 3 study. We expect to continue this good progress and to create products with meaningful benefits for patients.”
TiE is a global network dedicated to fostering entrepreneurs across its international network. Sponsored by top Venture Capital Firms and Fortune 500 corporations, TiE’s network has grown across 56 chapters in 13 countries comprising of 1,800 experienced entrepreneurs and business executives as charter members, 12,000 aspiring entrepreneurs and professionals as members.
Immatics biotechnologies is based in Tuebingen and Munich, Germany. Immatics is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer, and IMA950, which is phase 1 in patients with glioma.Immatics’ technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumor-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumor tissue – offer the prospect of greater effectiveness than existing therapeutic approaches combined with fewer side effects. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations and robust easily scalable manufacturing.